Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: A Markov modelling study

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages

  Ngalesoni, Frida N ^a,c   Ruhago, George M ^b,c   Mori, Amani T ^b,c   Robberstad, Bjarne ^c   Norheim, Ole F ^c  

^a MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cardiovascular disease; Cost effectiveness analysis; Diabetes; Markov modelling; Primary prevention; Societal perspective; Sub Saharan Africa; Tanzania

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; ECONOMICS; FEMALE; HUMAN; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; PRIMARY PREVENTION; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; TANZANIA; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; TANZANIA; TREATMENT OUTCOME;

EID: 84977500850     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1409-3     Document Type: Article

References (66)

1. Institute of Health Metrics and Evaluation. Global Heath Data Exchange - GBD Compare University of Washington, Seattle, WA, USA: 2013 [cited 2014 December].
2. Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S. The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum; 2011.
3. Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman D, Hertzmark E, et al. Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania. BMC Cardiovasc Disord. 2009;9(1):30.
4. Njelekela M, Negishi H, Nara Y, Tomohiro M, Kuga S, Noguchi T, et al. Cardiovascular risk factors in Tanzania: a revisit. Acta Trop. 2001;79(3):231-9.
5. Hendriks ME, Wit FWNM, Roos MTL, Brewster LM, Akande TM, de Beer IH, et al. Hypertension in sub-Saharan Africa: Cross-sectional surveys in four rural and urban communities. PLoS ONE. 2012;7(3):e32638.
6. Edwards R, Unwin N, Mugusi F, Whiting D, Rashid S, Kissima J, et al. Hypertension prevalence and care in an urban and rural area of Tanzania. J Hypertens. 2000;18(2):145-52.
7. Bovet P, Ross AG, Gervasoni JP, Mkamba M, Mtasiwa DM, Lengeler C, et al. Distribution of blood pressure, body mass index and smoking habits in the urban population of Dar es Salaam, Tanzania, and associations with socioeconomic status. Int J Epidemiol. 2002;31(1):240-7.
8. Aspray TJ, Mugusi F, Rashid S, Whiting D, Edwards R, Alberti KG, et al. Rural and urban differences in diabetes prevalence in Tanzania: the role of obesity, physical inactivity and urban living. Trans R Soc Trop Med Hyg. 2000;94(6):637-44.
9. David S, Till B. The economics of primary prevention of cardiovascular disease-a systematic review of economic evaluations. Cost Eff Resour Alloc. 2007;5(1):1.
10. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-Effectiveness analysis of hypertension guidelines in South Africa. Circulation. 2005;112(23):3569-76.
11. Ker JA. Decision making using cardiovascular risk reduction and incremental cost effectiveness ratio: a case study. Cardiovasc J Afr. 2008;19(2):97-101.
12. Robberstad B, Hemed Y, Norheim OF. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country - the case of Tanzania. Cost Eff Resour Alloc. 2007;5:3.
13. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361(9359):717-25.
14. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368(9536):679-86.
15. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112(23):3547-53.
16. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff. 2007;26(1):13-24.
17. Gaziano TA, Steyn K, Cohen DJ, Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in south africa: absolute risk versus blood pressure level. Circulation. 2005;112(23):3569-76.
18. Sanderson JE, Mayosi B, Yusuf S, Reddy S, Hu S, Chen Z, et al. Global burden of cardiovascular disease. Heart. 2007;93(10):1175.
19. Ministry of Health and Social Welfare. Standard Treatment Guidelines (STG) and the National Essential Medicine List (NEMLIT) for mainland Tanzania. Dar es Salaam: Ministry of Health and Social Welfare; 2007.
20. Ministry of Health and Social Welfare. Standard Treatment Guidelines and the Essential Medicine List (NEMLIT) Tanzania mainland. Dar es Salaam: Ministry of Health and Social Welfare; 2012.
21. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005;365(9457):434-41.
22. WHO. Prevention of cardiovascular disease: Guidelines for assessment and management of cardiovascular risk. Geneva: WHO; 2007. ISBN 978 92 4 154717 8.
23. National Vascular Disease Prevention Alliance. Absolute cardiovascular disease risk assessment 2014 [cited 2014 September]. Available from: https://heartfoundation.org.au/images/uploads/publications/Absolute-CVD-Risk-Quick-Reference-Guide.pdf.
24. Eberly LE, Cohen JD, Prineas R, Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality. Diabetes Care. 2003;26(3):848.
25. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288(21):2709.
26. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2129-43.
27. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994;25(1):40-3.
28. Anderson KM, WOLSON P, Odell PM, Kannel WB. An updated coronary risk profile: a statement fo rhealth professionals. Circulation. 1991;83(1):356-62.
29. Goff DC, Lloyd-Jones DM, Bennett G, O'Donnell C, Coady S, Robinson J. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2014;63(25-PA).
30. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care the Framingham Heart Study. Circulation. 2008;117(6):743-53.
31. WHO. Global Health Observatory Data Repository Life tables by country United Republic of Tanzania. Available from: http://apps.who.int/gho/data/?theme=main&vid=61770. Accessed Sept 2014.
32. Institute of Health Metrics and Evaluation. GBDX, Tanzania deaths, Both sexes, All ages, 2010. 2013 [cited 2014 July].
33. WHO. CHOosing Interventions that are Cost Effective (WHO-CHOICE). 2003. Available from: http://www.who.int/choice/cost-effectiveness/en/. Accessed Sept 2014.
34. Ngalesoni F, Ruhago G, Norheim OF, Robberstad B. Economic cost of primary prevention of cardiovascular diseases in Tanzania. Health Policy Plan. 2014;30(7):875-84.
35. Dror DM, Putten-Rademaker V, Koren R. Cost of illness: evidence from a study in five resource-poor locations in India. 2008. Available at SSRN 1016701.
36. Ezzati M, Vander Hoorn S, Rodgers A, Lopez AD, Mathers CD, Murray CJ. Estimates of global and regional potentil health gains from reducing muliple major risk factors. Lancet. 2003;362(9380):271-80.
37. The World Bank. World Development Indicators. 2014. Available from: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed Dec 2014.
38. WHO. Health Report 2002. Geneva: WHO; 2002.
39. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
40. Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press; 2011.
41. Drummond MF, Sculpher M, Torrance G, O'Brien B, Stoddart G. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
42. Barton GR, Briggs AH, Fenwick EA. Optimal Cost Effectiveness Decisions: The Role of the Cost Effectiveness Acceptability Curve (CEAC), the Cost Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI). Value Health. 2008;11(5):886-97.
43. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost effectiveness acceptability curves. Health Econ. 2001;10(8):779-87.
44. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
45. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and cost effectiveness in NICE-stepping back to sort out a confusion. Health Econ. 2006;15(1):1-4.
46. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Discounting and decision making in the economic evaluation of health care technologies. Health Econ. 2011;20(1):2-15.
47. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 2007;16(3):307-17.
48. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446-8.
49. Ortegón M, Lim S, Chisholm D, Mendis S. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ. 2012;344.
50. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold. Pharmacoecon. 2008;26(9):733-44.
51. Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb DM, et al. Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: Are current international norms fit for purpose? 2014.
52. Jones AM. The Elgar companion to health economics. Northampton, MA USA: Edward Elgar Publishing Cheltenham UK; 2012.
53. Shillcutt MSD, Walker DG, Goodman CA, Mills AJ. Cost effectiveness in low-and middle-income countries. Pharmacoecon. 2009;27(11):903-17.
54. Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives for health care decisions. 2010.
55. Polimeni JM, Vichansavakul K, Iorgulescu RI, Chandrasekara R. Why perspective matters in health outcomes research analyses. Int Bus Econ Res J. 2013;12(11):1503-12.
56. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357-9.
57. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417-28.
58. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;3(3):CD001841.
59. Medical Stores Department, Tanzania. Price Catalogue of Essential Medicines, Diagnostics and Hospital Supplies 2011\12.
60. Bangalore S, Kumar S, Wetterslev J, Messerli FH. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ. 2011;342:d2234.
61. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine. 2008;359(15):1577-89.
62. Law M, Morris J, Wald N. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
63. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.
64. Brugts J, Yetgin T, Hoeks S, Gotto A, Shepherd J, Westendorp R, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.
65. Garbusinski JM, van der Sande MA, Bartholome EJ, Dramaix M, Gaye A, Coleman R, et al. Stroke Presentation and Outcome in Developing Countries A Prospective Study in The Gambia. Stroke. 2005;36(7):1388-93.
66. Heikinheimo T, Chimbayo D, Kumwenda JJ, Kampondeni S, Allain TJ. Stroke outcomes in Malawi, a country with high prevalence of HIV: a prospective follow-up study. PloS one. 2012;7(3):e33765.